Home › Companies › LGVN

Longeveron Inc.

LGVN Rare disease Lead: Phase 2 10 Biotech Distilled articles ↓

Cardiovascular Metabolic Neurology Cell

Pipeline (4 active programs)

Lomecel-B

laromestrocel

Biotech Distilled coverage (10)

2026-05-14 UPDATE: Longeveron (LGVN) - The ATM Trap Snaps Shut
2026-05-09 UPDATE: Longeveron (LGVN) - The FDA Pulls the Pivotal Rug 🔒 Paid
2026-03-21 UPDATE: Longeveron (LGVN) - The 10-K Autopsy 🔒 Paid
2026-03-15 UPDATE: Longeveron (LGVN) - Surviving the Gap (But Pawning the Crown Jewel) 🔒 Paid
2026-03-07 UPDATE: Longeveron (LGVN) - The Reverse Stock Split and the Dilution Trap 🔒 Paid
2026-02-28 UPDATE: Longeveron (LGVN) - Scientific Validation vs. Financial Reality 🔒 Paid
2026-02-14 UPDATE: Longeveron (LVGN) - The Financial Fire Alarm is Ringing 🔒 Paid
2026-02-07 UPDATE : Longeveron (LGVN) - Rare Pediatric Disease PRV Program Reauthorized 🔒 Paid
2026-01-30 UPDATE: Longeveron (LGVN) - Regulatory Momentum & Manufacturing Moat 🔒 Paid
2026-01-06 Longeveron Inc (LGVN): Scientific Deep Dive for Lead and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.